Inhaled Nitric Oxide Market

Prevalence of Chronic Illnesses to Raise Demand of Inhaled Nitric Oxide

The Inhaled Nitric Oxide Market is valued at USD 1.1 Bn in 2026 and is projected to reach USD 2.1 Bn,  growing at a CAGR of 10% by 2033.Prevalence of several chronic illnesses has raised concerns among individuals and healthcare facilities alike, as mortality rates caused by such diseases continue to increase. This has resulted in adopting new therapies such as use of inhaled nitric oxide to treat illnesses such as COPD, Asthma and PPHN. Moreover, increasing deaths due to such diseases has propelled demand for inhaled nitric oxide as it regulates and improves vascular muscle tone. According to WHO, deaths due to asthma in 2019 were around 461,000 across the globe and is the most prevailing chronic illness, especially among children. On the other hand, COPD (Chronic Obstructive Pulmonary Disease) is considered as a third major cause of death, which, in 2019, resulted in 3.23 million fatalities worldwide. Moreover, according to North American Pediatric Pulmonary Hypertension Network Registry, cases related to PPHN (Persistent Pulmonary Hypertension in Newborn) are expected to increase and result in high mortality rate. Inhaled nitric oxide enhances oxygenation, thus reducing shunting while enhancing ventilation perfusion matching, which can be used in treating chronic illnesses such as PPHN, COPD and asthma. This aspect is expected to drive the growth of the inhaled nitric oxide market in the coming years.

Use of Inhaled Nitric Oxide in Fighting COVID 19 to Influence Growth

Research on use of inhaled nitric oxide in treating COVID 19 is currently being conducted. Being an endogenous vasodilator, use of inhaled nitric oxide to target pulmonary vasculature particularly in conditions where higher pulmonary vascular resistance is needed is being researched upon. By far, research shows that inhaled nitric oxide improves oxygenation, which is a key aspect in fighting COVID 19. Moreover, pre-intubation application of inhaled nitric oxide in patients suffering from respiratory failure due to COVID 19 is likely to have a significant impact in enhancing patient outcomes. Different physiological effects provided by inhaled nitric oxide, such as inflammatory response, anti-microbial effect, airway permeability, neurotransmission and ciliary motility can play a crucial role in treating wide range of indications and symptoms of COVID 19. Potential of inhaled nitric oxide as a therapeutic agent in fighting COVID 19 is likely to pave potential opportunities in the coming years, consequently fuelling growth of inhaled nitric oxide market.

Side Effects Associated with iNO to Impede Growth of Inhaled Nitric Oxide Market

Although inhaled nitric oxide (iNO) has its potential benefits in fighting chronic ailments, there are few side effects caused due to over use of the chemical. Its use in oxygenation is related to cellular cGMP (cyclic GMP), whose increased rate can interfere with and have an adverse effect on normal cellular proliferation. In addition inhaled nitric oxide can also lead to breaking or causing alterations in DNA strands that are mutagenic. Inhaled nitric oxide can sometimes react with oxygen to produce nitrogen dioxide that is a potentially harmful irritant. Overdose or incorrect administration of inhaled nitric oxide can also lead to blocking of platelet aggregation, in turn causing methemoglobinemia. However, the complete toxic nature of inhaled nitric oxide is still in its research phase, the conclusion of which is expected to raise questions on its administration. This factor is expected to hinder growth of the inhaled nitric oxide market.

Inhaled Nitric Oxide Market to Witness Potential Growth Avenues in North America

Growing incidences of ARDS (Acute Respiratory Distress Syndrome) in developed countries of North America have played a major role in driving growth of inhaled nitric oxide market. For instance, according to NCBI (National Center for Biotechnology Information), cases of ARDS in United States are between 64.2- 78.9 per 100,000 person years. In addition, according to analysis of AAFA (Asthma and Allergy Foundation of America), around 25 million people in the region suffer from asthma and the disease is more common among adult women than men. This has resulted in adopting therapies that facilitate oxygenation of lungs in turn improving vascular health, which is expected to drive growth of the inhaled nitric oxide market in North America.

Some of the key players operating in the inhaled nitric oxide market include 

• Mallinckrodt Pharmaceuticals
• INO Therapeutics LLC
• Air Products and Chemicals, Inc.
• Vero Biotech LLC
• Linde plc
• Air Liquide S.A.
• BOC Limited
• Nikko Chemicals Co., Ltd.
• Cryo Life, Inc.
• GE Healthcare
• Philips Healthcare
• Siemens Healthineers
• Smiths Group plc
• CONBIO Medical Systems, Inc
• Praxair, Inc.

By Application

• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease
• Acute Respiratory Distress Syndrome
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa